Dermatologic findings associated with semaglutide use: A scoping review
Journal of the American Academy of Dermatology · 2024-07 · 91 (1) · 166-168
DOI: 10.1016/j.jaad.2024.03.021 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2024-07. Verfasst von Megan M Tran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Warren Alpert Medical School, Brown University, Providence, Rhode Island. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Dermatologic findings associated with semaglutide use: A scoping reviewTo the Editor: Recent studies on semaglutide, a glucagon-like peptide-1 agonist, have shown its broad applicability and effectiveness in reducing cardiovascular risk in individuals with obesity, inducing sustained weight loss, and improving glycemic control in type II diabetes.[1][2][3] However, few studies have characterized skin findings in patients on this medication.Through this scoping review, we aim to investigate reported dermatologic adverse events associated with both subcutaneous and oral administrations of semaglutide.We conducted a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, utilizing PubMed, Embase, and Scopus databases on articles reporting dermatologic findings associated with semaglutide published until January 2024.Search strings were used to identify articles from these databases (Supplementary Methods, available via Mendeley at https://data.mendeley.com/datasets/3mxh852x4p/1).Duplicates were removed, and 2 authors independently extracted the data (M.M.T., A.C.L.).Uncertainties or discrepancies were discussed among these 2 authors, and a consensus was reached.Studies that specified another drug as the cause of the described adverse event were excluded.A total of 22 articles (15 clinical trials, 6 case reports, and 1 retrospective cohort study) were included (Supplementary Table I, available via Mendeley at https://data.mendeley.com/datasets/ djcggf9855/1).These articles describe semaglutideassociated dermatologic adverse events in 255 patients (Table I).Injection site reactions occurred in 3.5% of patients taking semaglutide; however, this was lower than the rate in the placebo and comparator groups (6.7%).For all other reports, adverse events were more frequently observed with semaglutide than the placebo or comparator groups.Oral administration of semaglutide 50 mg was associated
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Warren Alpert Medical School, Brown University, Providence, Rhode Island.
- Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
- Brown University, Providence, Rhode Island.
Zitieren
APA
Tran, M. M., Mirza, F. N., Lee, A. C., Goldbach, H. S., Libby, T. J., & Wisco, O. J. (2024). Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology, 91(1), 166-168. https://doi.org/10.1016/j.jaad.2024.03.021
Vancouver
Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology. 2024;91(1):166-168. doi:10.1016/j.jaad.2024.03.021
BibTeX
@article{Tran2024,
author = {Tran, Megan M and Mirza, Fatima N and Lee, Adrian C and Goldbach, Hayley S and Libby, Tiffany J and Wisco, Oliver J},
title = {Dermatologic findings associated with semaglutide use: A scoping review},
journal = {Journal of the American Academy of Dermatology},
year = {2024},
volume = {91},
number = {1},
pages = {166--168},
doi = {10.1016/j.jaad.2024.03.021}
}
EUVIMED